ArticleMolecular oncology2019
Prioritization of candidate cancer drugs based on a drug functional similarity network constructed by integrating pathway activities and drug activities.
Article in Molecular oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- Article
- DrugRepoBank: a comprehensive database and discovery platform for accelerating drug repositioning.Database : the journal of biological databases and curation · 2024Article
- ssMutPA: single-sample mutation-based pathway analysis approach for cancer precision medicine.GigaScience · 2024Article
- PathwayTMB: A pathway-based tumor mutational burden analysis method for predicting the clinical outcome of cancer immunotherapy.Molecular therapy. Nucleic acids · 2023Article
- DTSEA: A network-based drug target set enrichment analysis method for drug repurposing against COVID-19.Computers in biology and medicine · 2023Article
- Guiding Drug Repositioning for Cancers Based on Drug Similarity Networks.International journal of molecular sciences · 2023Article
- PANACEA: network-based methods for pharmacotherapy prioritization in personalized oncology.Bioinformatics (Oxford, England) · 2023Article
- Article
- Informatics on Drug Repurposing for Breast Cancer.Drug design, development and therapy · 2023Review
- DrugSim2DR: systematic prediction of drug functional similarities in the context of specific disease for drug repurposing.GigaScience · 2022Article
- Bioinformatics roadmap for therapy selection in cancer genomics.Molecular oncology · 2022Review
- Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic Pathway Signatures.Genes · 2022Article
- Computational Drug Repurposing Based on a Recommendation System and Drug-Drug Functional Pathway Similarity.Molecules (Basel, Switzerland) · 2022Article
- Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report.Frontiers in oncology · 2022Article
- Artificial Intelligence for Precision Oncology.Advances in experimental medicine and biology · 2022Review
- Lung Cancer Stage Prediction Using Multi-Omics Data.Computational and mathematical methods in medicine · 2022Article
- Identification of Somatic Mutation-Driven Immune Cells by Integrating Genomic and Transcriptome Data.Frontiers in cell and developmental biology · 2021Article
- Development and Validation of a Three-Gene Prognostic Signature Based on Tumor Microenvironment for Gastric Cancer.Frontiers in genetics · 2021Article
- A Random Walk with Restart Model Based on Common Neighbors for Predicting the Clinical Drug Combinations on Coronary Heart Disease.Journal of healthcare engineering · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the speed, efficiency, relative risk, and lower costs compared to traditional drug discovery, the prioritization of candidate drugs for repurposing against cancers of interest has attracted the attention of experts in recent years. Herein, we present a powerful computational approach, termed prioritization of candidate drugs (PriorCD), for the prioritization of candidate cancer drugs based on a global network propagation algorithm and a drug-drug functional similarity network constructed by integrating pathway activity profiles and drug activity profiles. This provides a new approach to drug repurposing by first considering the drug functional similarities at the pathway level. The performance of PriorCD in drug repurposing was evaluated by using drug datasets of breast cancer and ovarian cancer. Cross-validation tests on the drugs approved for the treatment of these cancers indicated that our approach can achieve area under receiver-operating characteristic curve (AUROC) values greater than 0.82. Furthermore, literature searches validated our results, and comparison with other classical gene-based repurposing methods indicated that our pathway-level PriorCD is comparatively more effective at prioritizing candidate drugs with similar therapeutic effects. We hope that our study will be of benefit to the field of drug discovery. In order to expand the usage of PriorCD, a freely available R-based package, PriorCD, has been developed to prioritize candidate anticancer drugs for drug repurposing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.